Navigation Links
The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinson's disease
Date:10/31/2011

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded a grant to Academy Professor Mart Saarma, PhD, and his team at the Institute of Biotechnology of the University of Helsinki. The funding will be used in conjunction with HermoPharma Company for the therapeutic development of the neurotrophic factor cerebral dopamine neurotrophic factor (CDNF) as a potential treatment for Parkinson's disease (PD).

Saarma's major breakthrough in this field was the discovery of CDNF, and he has performed subsequent demonstrations that it has potential to both protect and repair injured neurons in pre-clinical models of PD. MJFF has been funding Saarma's team to investigate CDNF since 2006, including a $500,000 award in 2010 to study the therapeutic potential of CDNF in pre-clinical models of PD. The newly-awarded grant will be used to further complete these studies.

PD is a disorder of the central nervous system that results from the loss of dopamine-producing brain cells. Neurotrophic factors are are proteins that promote the survival, growth and function of neurons in the brain, and therefore, are of major interest to PD researchers.

Saarma's team and a team headed by Professor Raimo K. Tuominen, MD, PhD, of the Faculty of Pharmacy, have in the past compared the neuroprotective and neurorestorative properties of CDNF with those of other neurotrophic factors like glial cell line-derived neurotrophic factor, or GDNF. The results were promising in terms of developing CDNF as a novel treatment for PD.

Future pre-clinical studies on the efficacy of CDNF on PD are being carried out in collaboration with Judy L. Cameron, PhD, of the University of Pittsburgh and with Zhiming Zhang, MD, of the University of Kentucky.


'/>"/>

Contact: Mart Saarma
mart.saarma@helsinki.fi
358-505-002-726
University of Helsinki
Source:Eurekalert

Page: 1

Related biology news :

1. LLNL selects Madhav Marathe for the first George A. Michael Distinguished Scholar Award
2. Dr. Michael Collins publishes paper on ivory-billed woodpecker
3. Michael S. Watson, Ph.D., receives Am College of Medical Genetics-ACMG Foundation Presidents Award
4. 2011 HFSP Nakasone Award for Michael Elowitz of Caltech
5. Michael Graetzel wins the Millennium Technology Prize
6. Adult Star Katie Michaels Attending NHL Game 7 Red Wings vs. Coyotes
7. Michael Betenbaugh wins 2010 Cell Culture Engineering award
8. American Society for Microbiology honors J. Michael Miller
9. Pacific Biometrics, Inc. Announces the Appointment of Michael Murphy, PhD as Chief Operating Officer
10. Annual Michael & Susan Dell lectureship in child health
11. National Science Foundation makes first awards in Sustainability Research Coordination Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/11/2014)... of all vertebrates, information is transmitted through synapses, ... signal to be passed from one brain cell ... abundant type of synapse, can be either excitatory ... memory, perception and cognition, and the balance between ... For instance, every time we learn something, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... shellfish, snails and other animals from the Pacific Ocean ... was interrupted by cooling conditions three million years ago, ... of California, Davis, and Peter Roopnarine at the California ... ice-free Arctic Ocean by 2050. That will restore conditions ...
... Pharmacy researchers have discovered a marine compound off the ... in laboratory tests, a finding they hope will fuel ... disease. The UF-patented compound, largazole, is derived from ... results from early studies today (Aug. 7) at an ...
... The University of Houston department of health and human performance ... a study promoting healthy dietary habits and physical activity. ... of Second Life (SL). , ... is part of the UH Texas Obesity Research Center,s (TORC) ...
Cached Biology News:Pacific shellfish ready to invade Atlantic 2Researchers find cancer-inhibiting compound under the sea 2Researchers find cancer-inhibiting compound under the sea 3TORC at UH turns to virtual world of Second Life for new study 2
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... - Appointment Enhances Algeta,s Commercial Capabilities ... Cancer , Algeta ASA ... Kay has been appointed as President and Chief,Executive Officer and ... Thomas,Ramdahl will continue as Executive Vice President and Chief Technology,Officer ...
... TUSTIN, Calif., Dec. 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... its Board of Directors, unexpectedly passed away on Wednesday. Dr. ... chairman since 2005. At the time of his death, Dr. ... , , "The sudden ...
... Alimera Sciences Inc., a privately held,biopharmaceutical company ... prescription ophthalmic pharmaceuticals, today reported,that enrollment has begun ... and efficacy,of Iluvien(TM) in patients with bilateral geographic ... The pilot ...
Cached Biology Technology:Algeta Appoints Andrew Kay as President and Chief Executive Officer 2Algeta Appoints Andrew Kay as President and Chief Executive Officer 3Algeta Appoints Andrew Kay as President and Chief Executive Officer 4Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
...
Biology Products: